RAC - Charts & Price Action, page-8890

Even though we know that the share market is not an environment where logic and rationality are constant its still hard not to raise an eyebrow at the RAC share price over the previous 6 months. That aside, there has been great progress made along with some welcomed surprises over the last 6 months and there is no reason not to expect more of that to come... the Race team have proven that they keep themselves very busy and have an exceptional output rate.

Here's just a few predictions for what the future may hold for RAC (and its share price) over the next 6 months.

1 - RAC is working at least one (potentially more) unknown projects, an educated guess is one project is a diagnostic tool

• Every time Dr T is asked about diagnostic tools we get a response "price sensitive" and rebutted people who suggested RAC wasn't capable of developing its own diagnostic tool.
• We had the recent investor presentation showing "other news" to come and continual comments from the team that RAC is more of an iceberg.
• It seems quite clear that to be 'precision oncology' drug you have to be able to target where your drug will be effective... targeting requires identification.
• Expect that the IP is being lodged if it has not already been lodged and is under review.

2 - Parties outside of RAC are currently using Zantrene for FTO research and we will see the results published

• Every time Dr T is asked about Chen's work with RAC, we get a "price sensitive" response.
• Both the City of Chicago and COH have highlighted that Zantrene appears to be the BIC FTO inhibitor.
• Much of the first round of research on FTO inhibitors was undertaken before the COH paper identified CS1 as the BIC inhibitor. With 12 months past since the COH paper, one would expect CS1 would get a lot more focus from researchers.
• RAC spent an amount of funds in the past 12 months on production of Zantrene which didn't appear to be linked to any particular RAC driven study at the time.
• COH have previously stated that the wish to undertake further research with Zantrene and many posters have identified that this paper should be due.
• We may start to see some FTO research outside of the cancer space and in other diseases e.g. diabetes

3 - BG selling down will be a distant memory

• At any other company if a major shareholder was selling down like this we would expect to see the board arrange a block trade with a friendly party (investor or fund). As this hasn't happened over the previous six months one would assume that they either have more important things to work on or something they are working on now means that this sell down by BG won't be an issue. The team members definitely have the capability and contacts to facilitate a block trade.
• RAC have previously mentioned that they plan to start talks with large Pharma groups in this quarter... you would assume they would also talk to US biotech funds at this time.
• Funds from options conversions are important to RAC, they have previously stated that these allow them to accelerate the clinical work and broaden their research. I doubt the RAC team will be leaving this up to chance and hope.